Shelf life (days): 1460.0
Formulation: A solid
Formal Name: N-ethyl-2-[[4-[7-[[trans-4-[(ethylsulfonyl)amino]cyclohexyl]methyl]-2,7-diazaspiro[3.5]non-2-yl]-5-pyrimidinyl]oxy]-5-fluoro-N-(1-methylethyl)-benzamide
Purity: ≥98%
Formula Markup: C32H47FN6O4S
Formula Weight: 630.8
CAS Number: 2169919-21-3
Notes: SNDX-5613 is a derivative of VTP-50469 (Item No. 40759), an inhibitor of the protein-protein interaction between menin and mixed-lineage leukemia 1 (MLL1), also known as lysine methyltransferase 2A (KMT2A). It inhibits the growth of patient-derived acute myeloid leukemia (AML) cells expressing the gene encoding upstream binding factor (UBF) and containing tandem duplications (UBF-TDs) when UBF-TD-containing AML cells are co-cultured with mesenchymal stem cells.{66821} SNDX-5613 (50 mg/kg) reduces disease burden and improves survival when used alone and, to a greater extent, when used in combination with the CBP and p300 inhibitor GNE-781 (Item No. 36450) in a MOLM-13 mouse xenograft model.{66822} It also reduces disease burden and increases survival in patient-derived xenograft (PDX) mouse models in which tumor cells contain rearrangements in the gene encoding KMT2A or mutations in the gene encoding nucleophosmin 1 (NPM1).{66823}
English
Deutsch
